Interventional cardiology news to note
Interventional therapy for four high-risk patients with Barlow's disease was possible with the MitraClip XTR's longer arm and better grasping mechanism, operators reported in EuroIntervention.
Staying 2 or more days in the hospital for elective percutaneous coronary intervention was tied to higher odds of 30-day readmission, on top of higher costs. This uptick in readmissions was driven more by heart failure than non-cardiac causes. (American Journal of Cardiology)
ST-segment elevation MI (STEMI) patients getting modern stents did just as well with 6 months of dual antiplatelet therapy as they with the full 12 months, according to the DAPT-STEMI trial published in The BMJ. Read MedPage Today's previous coverage of this trial.
Mechanical thrombectomy with the novel Versi Retriever was associated with good functional outcomes at 90 days for 72.7% of acute ischemic stroke patients, according to its first-in-man experience at a single center. TICI 3 revascularization was achieved in 63.6%. (Journal of NeuroInterventional Surgery)
Patients with complex femoropopliteal lesions -- typically excluded from trials -- may still benefit from drug-coated balloon treatment, according to a study in Journal of Endovascular Therapy.
Transcatheter pulmonary valve replacement using the Sapien device in a dysfunctional right ventricular outflow tract was durable out to 3 years. Freedom from all-cause mortality and reintervention were 98.4% and 93.7%, respectively, researchers reported. (JACC: Cardiovascular Interventions)
Markers of renal and kidney function were found to be predictors of long-term mortalityafter MitraClip therapy in high-risk patients, a retrospective Clinical Cardiology study suggested. "Thus, cystatin C and NGAL assessment may be helpful in risk stratification in patients undergoing percutaneous mitral valve repair," the authors suggested.
Read the original article on Medpage Today: Cath Lab Recap: MitraClip for Barlow's Disease; New Stent Retriever